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INTRODUCTION
Adequate vitamin D (25OHD) and parathyroid hormone
(PTH) levels are crucial for bone health. Vitamin D
deficiency (VDD) causes a decrease in intestinal
calcium absorption and produces secondary hyper-
parathyroidism (sHPTH) which is the primary mediator
of the detrimental effects of VDD on skeleton.1 Recently,
role of sHPTH in producing hypertension and ventricular
hypertrophy has been shown. sHPTH has been linked to
cardiovascular mortality in patients with heart failure.
Potential benefits have been observed after raising the
levels of 25OHD and thus lowering of PTH levels in
many chronic diseases.2-7
A high prevalence of VDD has been identified in
Pakistan in healthy volunteers and medical clinic
patients. A great concern was that 94.6% of adults were
between 20-30 years old; the age at which peak bone
mass is achieved and sHPTH was present in 31% of
individuals.8,9 Recent reports from two different public
hospitals in Karachi, demonstrated high prevalence of
VDD in pregnant women and their newborns urging for
an immediate action to the problem.10,11
sHPTH is reversible when 25OHD levels rises, however,
the optimal dose of 25OHD needed to normalize PTH is
currently taken as 75 nmol/l (32 ng/ml) by most
experts.1,12 In order to correct VDD, the practice pattern
of physician varies. Different protocols have been
proposed and strategies studied recently for vitamin D
supplementation. However, there is no universally
accepted regimen and treatment practice.13-18 A recent
trial demonstrated that the dose-response curve of
serum 25OHD concentration to the cholecalciferol
(vitamin D3) supplementation is widely variable,
suggesting that people may respond differently in terms
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of serum 25OHD increases to a fixed dose of chole-
calciferol.16
Studies published in recent years have focused mainly
on hypovitaminosis D and on the optimal treatment
capable of normalizing 25OHD and the dose of
cholecalciferol needed to normalize sHPTH.13-15
The present study was conducted with the aim of
determining the changes produced in serum vitamin D
and iPTH levels after a single intramuscular injection of
600,000 IU of cholecalciferol in patient with VDD.
METHODOLOGY
An interventional study was conducted in the Depart-
ment of Pathology and Microbiology, the Aga Khan
University (AKU) from June 2009 to June 2010. The
study was funded by Higher Education Commission
(HEC) of Pakistan and was approved by Ethical Review
Committee (ERC) of the Aga Khan University Hospital
(AKUH).
Volunteers of either gender aged 18-40 years whose
25OHD level had been checked within last one week at
the clinical laboratory of the AKUH, Karachi were
contacted by telephone. The aims of the study were
explained to them. On a pre-determined day, the
participants were requested to visit the Clinical
Laboratory of AKUH. A written informed consent was
obtained from all the participating individuals. Before
inclusion in the study, it was ensured that the serum
creatinine (Cr), calcium (Ca) and phosphorous (P) of the
volunteers were within normal limits.
Those volunteers who were taking any drug which could
confound the results like vitamin D supplements,
corticosteroids or anti-epileptic medicines were excluded
from the study. Other exclusion criteria were primary
hyperparathyroidism and hypercalcaemia, presence of
any other co-morbidity like renal failure, liver disease
and history of malabsorption, diarrhea or hyperthyroidism.
All volunteers irrespective of their 25OHD status were
given an intramuscular injection of vitamin D3 (Chole-
calciferol, 600,000 IU). Two months later, volunteers
were contacted and invited again to come to Clinical
Laboratory. During this visit their serum 25OHD, intact-
PTH (iPTH), Ca and P levels were determined again.
Venous blood was drawn in fasting volunteers between
8:00 - 10:00 am in plain serum tubes for Ca, P and
25OHD, and in EDTA tubes for iPTH analysis.
Immediately after phlebotomy, serum was separated
from the blood samples by centrifugation, aliquot and
preserved for 25OHD and iPTH levels at -20ºC until
analysis.
25OHD was measured by an electrochemiluminescence
immunoassay (ECLIA) performed on Elecys 2010
(Roche Diagnostics, USA). For quality control, Elecsys
Preci Controls in various concentration ranges was run
with each batch. Results were accepted only if the
concentration was within the defined limits of the pre-
control.
iPTH was measured by a solid-phase, two site chemilu-
minescent enzyme-labelled immunometric assay on
Immulite (Siemens Medical Solutions Diagnostics,
USA). Low and high levels of quality control samples of
iPTH were run with each batch. Interassay precision
(pg/ml) was found to have a range of 8.6%-9.0%.
Ca, P and Cr levels were assessed on Beckman Synchron
Cx7 by enzymatic methods; Arsenazo dye method for C,
Jaffe reaction for Cr and Phosphomolybdate reaction for
P. Low, medium and high Beckman commercial controls
were run with every batch as quality control.
Statistical Package for Social Sciences (SPSS) [release
13.0] standard version, copyright © SPSS, was used for
data analysis. For 25OHD, cut-off of ≤ 50 nmol/l was
defined as deficient, 50-75 nmol/l as insufficient and ≥ 75
as optimal levels.
Data was checked for normality by histogram.
Descriptive analysis was done for demographic and
laboratory tests. Percent increase and decrease in
25OHD and iPTH were calculated using standard
equations. The data are presented as mean ± standard
deviation. The association between serum 25OHD and
iPTH concentrations was studied by linear regression
and correlation. The statistical analysis for the
differences in the levels of 25OHD, iPTH, Ca and P
before and after vitamin D supplemen-tation was made
using paired t-test. A p-value of less than 0.05 was
considered statistically significant.
RESULTS
Twenty volunteers (6 males and 14 females) participated
in the study. The mean age of the participants was
27 ± 3.5 years. The mean BMI of males and females was
26.8 ± 2.7 and 24.1 kg/m2, respectively. Change in
serum 25OHD and iPTH values in individual volunteers
and their mean values at baseline and at follow-up, 8
weeks after injection Cholecalciferol are shown in
Table I and Figure 1.
At baseline, 17 volunteers were deficient in 25OHD with
serum levels < 50 nmol/l, one had serum levels of 76.97
nmol/l (optimal ≥ 75 nmol/l) and 2 had insufficient
25OHD serum levels (50-75 nmol/l). Mean serum
25OHD levels and iPTH levels were 35.06 ± 16.23
nmol/l and 81.15 ± 76.78 pg/ml, respectively. Five of the
volunteers (25%) had high iPTH levels with mean serum
levels of 156 ± 123.7 pg/ml. Baseline serum Ca and P
levels were within normal range; 2.3 ± 0.12 mmol/l and
0.9 ± 0.13 mmol/l. Serum 25OHD and iPTH showed
significant inverse correlation (r2 = 0.187, p < 0.01) at
baseline (Figure 2A).
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Table I: Percent change in serum 25OHD (nmol/l) and iPTH (pg/ml) levels after 600,000 IU intramuscular injection of cholecalciferol (N = 20).
Subjects Pre-treatment Post treatment % change Pre-treatment Post-treatment % change
250HD 250HD iPTH iPTH iPTH
1 9.98 63.09 532.0 377.0 34.0 90.0
2 21.71 87.98 30.5 79m .3 47.3 40.0
3 42.80 76.62 79.0 94.3 52.3 44.0
4 22.61 92.85 310.0 68.0 62.2 8.5
5 37.81 66.44 75.7 73.4 71.4 2.7
6 38.68 48.69 25.81 107.0 42.1 60.0
7 22.16 84.88 232.9 111.0 85.5 22.0
8 40.01 72.55 81.34 58.9 42.2 28.0
9 14.52 59.47 309.45 61.2 35.0 42.0
10 28.10 48.69 73.26 49.8 97.0 -94.0
11 24.26 42.43 74.89 39.3 45.0 -14.0
12 18.37 53.04 188.7 62.6 60.5 3.362
13 76.97 124.84 62.19 66.0 24.8 62.0
14 54.01 67.49 24.95 54.7 18.0 67.0
15 23.33 42.45 81.92 54.0 45.3 16.0
16 39.23 57.40 46.3 67.5 33.7 50.0
17 49.34 25.20 -48.91 91.6 11.6 87.0
18 44.90 89.23 98.72 36.8 36.8 0.0
19 39.33 63.79 62.18 60.3 46.5 22.0
20 52.99 65.39 23.41 21.5 30.7 42.0
Mean±SD 35.06±16.23 66.63±24.99 134.4±141.87 81.0 46.0 43.0
p-value < 0.01 - 0.05 -
Figure 1 (A,B): Response of 25OHD (nmol/l) and iPTH levels (pg/ml) to 600,000 IU of injection cholecalciferol in healthy volunteers in Karachi, Pakistan (n = 20).
Table II: Response of 25OHD (ng/ml) and iPTH (pg/ml) to different dosing regimen of Cholecalciferol supplementation in literature.
VD (IU) N Route Dosing Baseline 2 months 3 months 4 months 6 months 1 year Ref
interval 250HD PTH 250HD PTH 250HD PTH 250HD PTH 250HD PTH 250HD PTH
1000 30 oral Daily 23.4 92.5 - - 49.6 70.2 - - 57.6 66.0 - - 16∞
60,000 23 oral Weekly * 13.5 54.0 82.4 29.0 - - - - - - 24.7 10.9 13
60,000 40 oral Weekly*** 25.4 - 94.5 - - - - - 56.0 - - - 17
300,000 30 oral Monthly** 22.0 99.9 - - 51.4 78.0 - - 78.2 72.9 - - 16
600,000 50 IM Single 32 7.4 - - - - 112.0 6.0 - - 73.0 5.2 14
600,000 20 oral Single 42.9 57.0 106.8 42.8 79.6 37.7 - - - - - - 18∞
600,000 40 IM Single 22.8 122.0 - - 69.1 24.8 - - - - - - 15∞
600,000 20 IM Single 35.06 81.0 66.7 46.0 - - - - - - - - This
study
* Weekly for 4 months;     ** Once at baseline and once at 3 months;     *** Weekly for 8 weeks followed by 60,000 IU/month for 4 months.
∞ Values of 25OHD from reference 15, 16 & 18 are converted from ng/ml to nmol/l;    ∞ Value of i PTH from reference 14 are in pmol/l.
After 8 weeks of injection vitamin D (600,000 IU), serum
25OHD levels became optimal (≥ 75 nmol/l) in 6
volunteers (35%) (mean 92.72 ± 16.65 nmol/l). It
remained low in 5 volunteers (25%) (mean 41.48 ± 9.62
nmol/l), while insufficient levels were seen in 9
volunteers (40%) (mean 63.19 ± 5.88 nmol/l). Follow-up
mean serum Ca, P and iPTH were 2.5 ± 0.10 mmol/l,
1.16 ± 0.13 mmol/l and 47.52 ± 22.56 pg/ml respectively.
In one individual, despite increase in 25OHD levels, the
iPTH levels increased.
Mean baseline 25OHD levels (35.06 ± 16.23 nmol/l)
were significantly different from follow-up (66.63 ± 24.99
nmol/l) 25OHD levels (p < 0.01) while significant
difference was not seen in baseline (81.15 ± 76.78
pg/ml) and follow-up (47.52 ± 22.56 pg/ml) iPTH levels
(p = 0.05) (Figure 1A and B).
Mean follow-up serum Ca (2.5±0.10 nmol/l) and
P (1.1 ± 0.13 nmol/l) did not show significant change
(p = 0.47 and 0.46 respectively) from baseline values
of Ca (2.3 ± 0.11 nmol/l) and P (0.9 ± 0.13 nmol/l). The
inverse correlation seen in the baseline samples
between iPTH and 25OHD changed to r2 = 0.03
(Figure 2B).
DISCUSSION
In Pakistan, VDD is widely prevalent despite adequate
sunshine throughout the year. Serum 25OHD levels
observed at baseline in the current study and sHPTH in
25% of the study participants further supported the
previous findings and endorsed the wide spread
existence of 25OHD deficiency along with sHPTH.7,8,19-21
With recent greater awareness about VDD, testing for
25OHD has become common in diagnosing and treating
VDD.
A controvesial aspect in the setup is the treatment
strategies of correcting VDD. Several strategies have
been reported recently in literature using oral and
injectable vitamin D preparations of 1,000-600,000 IU
and with variable outcomes (Table II). In a report from
India, pattern of 25OHD response at 2 months and one
year interval of giving 60,000 IU of cholecalciferol per
week was evaluated in 28 subjects. VDD was corrected
in all subjects at 8 weeks with normalization of PTH.
However, at one year follow-up all subjects develop
VDD with sHPTH, indicating need for ongoing
supplementation for sustaining 25OHD levels.13
In Karachi, oral vitamin D supplementations are
available in combination with calcium supplement with
most of the available oral preparations containing
100-125 units of cholecalciferol; only a few contains
400 IU of cholecalciferol. In addition, two depot
intramuscular preparations of 200,000 and 600,000 IU
of cholecalciferol are also available. Treatment of VDD
with oral preparations is much more expensive as
compared to injections.
Practice patterns of physicians in treating VDD are also
widely variable,20 with some physicians prescribing two
injections one month apart while others prescribe 3
injections of vitamin D at two weekly intervals. Another
practice is to give 600,000 units intramuscularly every
3 months; cases have been seen (personal observation)
in which alternate day injections of 600,000 IU have
been prescribed for 1-2 months. At the same time, some
physicians treat the patients with severe VDD with low
dose oral preparation and hence results in treatment
failure. Very few physicians perform complete bio-
chemical testing to assess the response to sHPTH
associated with VDD and insufficiency to vitamin D
replacement. The effects of these mega doses have
not been studied in our setting and practices are based
on individual experiences. Information regarding
effective correction of VDD with currently available depot
preparation is lacking in our population. In Pakistani
immigrant in Denmark recently, effects of low dosages of
400 and 800 IU/day (10 and 20 µg/day) were studied at
6 and 12 months after intervention. Increases in 25OHD
were observed in study participants, but optimal levels
were not achieved. However, this degree of intervention
did not have any significant effect on bone turnover
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Figure 2 (A,B): Association between 25OHD (nmo/l) and iPTH (pg/ml) before and after 8 weeks of injection cholecalciferol (600,000 IU).
marker and DEXA measurement.23 While, in another
study a dose of 22 µg/day of vitamin D increased the
serum concentration to optimal levels in white young
adult women residing in Orono, Maine.24 Higher intakes
are recommended for South Asian populations,12,23 but
the controversy remains about which concentration of
serum 25OHD should constitute the lower limit of
adequacy especially for South Asian population.
Deficiency is defined as the 25OHD level below which
serum PTH concentration increases. Estimates of
25OHD required for maximal suppression of PTH varies.
However, the most widely acceptable cutoff is 75 nmol/l
(30 ng/ml).
In a study conducted in Sydney to assess the efficacy
and safety of annual 600,000 IU of cholecalciferol for
treatment of VDD, 50 vitamin D-deficient participants
were evaluated at baseline and after 4 and 12 months of
therapy. Significantly higher levels of 25OHD were seen
at 4 months, and 12 months compared with baseline
while there was a 30% decline in PTH levels at 12
months. 25OHD levels increased by 128% over 12
months. Recommendations were made to further
assess the efficacy of this mega dose as it is cost
effective as compared to oral forms of treatment, and
have simple dosing regimen thus improving patient
compliance.14
On the other hand, in another study conducted in Qatar,
Doha, 37 out of 40 adolescents before, 3 and 6 month
after treatment with a single mega dose of
cholecalciferol showed mean levels of 67.3 nmol/l with
significant improvements in symptoms for 3 months.
Recommendations from this study support the
effectiveness of this dose of VD for 3 months.15
In this study, vitamin D levels were optimally achieved
in 35% of the subjects post-injection. There is wide
variation in the biochemical response to vitamin D
injections (Table I). Though the change in 25OHD level
in baseline and follow-up is statistically significant;
but the baseline and post-injection mean change in iPTH
is not statistically significant with a single mega dose.
Further research is needed at different follow-up
intervals to assess the effectiveness of vitamin D
therapy and to determine how much vitamin D is
required to optimize serum 25OHD status throughout
the year for optimal physiological functioning.
We recommend that a single mega dose of vitamin D
may not achieve optimal levels of 25OHD in all
individuals. In order to confirm the adequacy of
treatment a repeat testing should be performed to
assess 25OHD levels between 8-12 weeks of
supplementation to confirm that the target 25OHD level
has been reached. It is important to acquaint physicians
in Pakistan that  repletion dose of vitamin D may vary
among individuals based on their initial levels, body
mass index and effective sunlight exposure. The
required dose to acquire 75 nmol/l can be estimated
from measured levels; as each 100 IU of vitamin D
increases the 25OHD levels to 1.0 ng/ml. It is equally
important to emphasize on life style measures like safe
exposure to sunlight and diet and supplements to
acquire the recommended daily allowance of 800-1000
IU for older age groups. It is important to understand that
over-the-counter active metabolites are not a substitute
for adequate vitamin D intake and should not be used to
treat vitamin D deficiency. Long-term follow-up to assess
the relationship between VDD and iPTH and potential to
develop hypercalciuria with excess use of VD is needed
in our population.
CONCLUSION
Single mega-dose of cholecalciferol achieve optimal
levels of 25OHD in 35% of subjects after 8 weeks of
supplementation.
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